These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2533902)

  • 1. Pharmaceutical development of ondansetron injection.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical development of ondansetron tablets.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S63-6. PubMed ID: 2533901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
    Trissel LA; Tramonte SM; Grilley BJ
    Am J Hosp Pharm; 1991 May; 48(5):988-92. PubMed ID: 1830190
    [No Abstract]   [Full Text] [Related]  

  • 4. Stability of ondansetron hydrochloride in portable infusion-pump reservoirs.
    Stiles ML; Allen LV; Fox JL
    Am J Hosp Pharm; 1992 Jun; 49(6):1471-3. PubMed ID: 1388331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions.
    McGuire TR; Narducci WA; Fox JL
    Am J Hosp Pharm; 1993 Jul; 50(7):1410-4. PubMed ID: 8362872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical and chemical stability of pemetrexed in infusion solutions.
    Zhang Y; Trissel LA
    Ann Pharmacother; 2006 Jun; 40(6):1082-5. PubMed ID: 16720706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22, and 32 degrees C.
    Trissel LA; Xu Q; Martinez JF; Fox JL
    Am J Hosp Pharm; 1994 Sep; 51(17):2138-42. PubMed ID: 7527184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of a single intravenous dose of ondansetron.
    Brown GW; Paes D; Bryson J; Freeman AJ
    Oncology; 1992; 49(4):273-8. PubMed ID: 1387927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical and chemical stability of palonosetron HCl in 4 infusion solutions.
    Trissel LA; Xu QA
    Ann Pharmacother; 2004 Oct; 38(10):1608-11. PubMed ID: 15328393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of ondansetron and dexamethasone infusion upon refrigeration.
    Rolin C; Hecq JD; Vanbeckbergen DF; Jamart J; Galanti LM
    Ann Pharmacother; 2011 Jan; 45(1):130-1. PubMed ID: 21156815
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability of intravenous admixtures of doxorubicin and vincristine.
    Beijnen JH; Neef C; Meuwissen OJ; Rutten JJ; Rosing H; Underberg WJ
    Am J Hosp Pharm; 1986 Dec; 43(12):3022-7. PubMed ID: 3812509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions.
    Graham CL; Dukes GE; Fox JL; Kao CF; Hak LJ
    Am J Hosp Pharm; 1993 Jan; 50(1):106-8. PubMed ID: 8427264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4 degrees C.
    Jhee SS; Jeong EW; Chin A; Inagaki K; Fox JL; Gill MA
    Am J Hosp Pharm; 1993 Sep; 50(9):1918-20. PubMed ID: 8135242
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
    Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron: design and development of oral pharmaceutical suspensions.
    Gallardo Lara V; Gallardo ML; Morales Hernandez ME; Ruiz Martinez MA
    Pharmazie; 2009 Feb; 64(2):90-3. PubMed ID: 19320280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
    Cheung YW; Cradock JC; Vishnuvajjala BR; Flora KP
    Am J Hosp Pharm; 1987 Jan; 44(1):124-30. PubMed ID: 3548341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium.
    Beran C; Howard MS; Baki G; Churchwell MD
    Int J Pharm Compd; 2024; 28(4):329-333. PubMed ID: 39094045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cimetidine hydrochloride compatibility. II: room temperature stability in intravenous infusion fluids.
    Yuhas EM; Lofton FT; Mayron D; Baldinus JG; rosenberg HA
    Am J Hosp Pharm; 1981 Jun; 38(6):879-81. PubMed ID: 7246564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism of ondansetron.
    Saynor DA; Dixon CM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S75-7. PubMed ID: 2533904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.